Table 2.
mAbs targeting EGFR pathway under clinical investigation.
| Drugs | Target | Setting | Treatment | Phase | Identifiers |
|---|---|---|---|---|---|
| Trastuzumab | HER2 | HER2-positive wild KRAS mCRC | Trastuzumab + Lapatinib or Pertuzumab | II | NCT03225937 |
| Trastuzumab + Tucatinib | NCT03043313 | ||||
| Pertuzumab | HER2 | 2nd line of advanced or mCRC | Pertuzumab + cetuximab | I/II | NCT00551421 |
| MEHD7945A (Duligotuzumab) | EGFR/HER3 | 2nd line K-Ras wild-type mCRC | MEHD7945A + FOLFIRI vs. Cetuximab + FOLFIRI | II | NCT01652482 |
| SYM004 | EGFR | mCRC K-Ras WT acquired resistance to Anti-EGFR mAbs | SYM004 vs. BSC | II | NCT02083653 |
| CPGJ 602 | EGFR | 2nd line mCRC KRAS WT | CPGJ 602 vs. Cetuximab | I | NCT03356158 |
| Futuximab | EGFR | Chemotherapy-refractory mCRC | Futuximab vs. SYM004 | II | NCT03549338 |
| SCT 200 | EGFR | Wild-type RAS and RAF mCRC | SCT200 | II | NCT03405272 |
| Dalotuzumab (MK-0646) | IGF-1R | Wild-type KRAS mCRC | Dalotuzumab + Cetuximab + irinotecan | II/III | NCT00614393 |
| Ganitumab (AMG-479) | IGF-1R | Mutant KRAS mCRC | AMG-479 + FOLFIRI vs. FOLFIRI alone | II | NCT00813605 |
| Cixutumumab (IMC-A12) | IGF-1R | 2nd line mCRC kRAS wild-type | Irinotecan and Cetuximab ± IMC-A12 | II | NCT00845039 |
mAbs: monoclonal antibodies; mCRC: metastatic colorectal cancer; FOLFIRI: irinotecan in combination with 5-fluorouracil and folinic acid; BSC: best supportive care; HER: human epidermal growth factor receptor; EGFR: epidermal growth factor receptor; IGF-1R: insulin-like growth factor 1 receptor; KRAS: Kirsten rat sarcoma viral oncogene.